Loading stock data…
$6.17-0.26 (-4.04%)
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.
LeonaBio, Inc. in the Healthcare sector is trading at $6.17 with a market capitalization of $54M. Wall Street consensus targets $17.33 (3 analysts), implying a +180.9% move over the next 12 months. The stock is currently 57% below its 52-week high of $14.21, remaining 19.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.28M↓ | -$18.14M↓ | -$10.48M↓ | -$6.87M↑ | -$7.29M |
| Net Income | -$19.01M↑ | -$32.95M↑ | -$82.89M↓ | -$6.61M↑ | -$6.97M |
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead prod...